A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions

Asthma

Interventions

BIOLOGICAL

omalizumab

Trial Locations (1)

Novartis Investigative Site, Montreal